Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CTRC | Q99895 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5395885 | 0.98 | HTR1A (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL5405213 | 0.76 | CA2 (0.33) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL457900 | 0.75 | HTR1A (0.37) | HTR1ADRD2HTR2AHTR7HTR6 | |
| SCHEMBL2329649 | 0.74 | KDM4E (0.36) | HTR1ADRD2HTR2AHTR7HTR6 | |
| Methane SCHEMBL16027128 | 0.72 | TLR8 (0.41) | TLR8TYRSKP2CTRCGABRP | |
| Hydrochloric Acid SCHEMBL6593571 | 0.69 | ALDH1A1 (0.43) | CSNK2A1 | |
| Hydroxyamine SCHEMBL27830404 | 0.68 | ALOX5 (0.40) | HTR2ATLR8TYRGABRPGABRD | |
| SCHEMBL174991 | 0.68 | TLR8 (0.43) | HTR2ATLR8TYR | |
| SCHEMBL30663935 | 0.66 | DPP4 (0.44) | TLR8 | |
| SCHEMBL27610566 | 0.66 | DPP4 (0.44) | TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | claimed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | claimed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | claimed |
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2013-02-21 | — | — | US | disclosed |
| EP-2533636-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | Mapi Pharma Limited (IL) | 2012-12-19 | — | — | EP | disclosed |
| CN-102753018-A | Preparation of benzofurans and their use as synthetic intermediates | MAPI PHARMA HOLDINGS CYPRUS LTD | 2012-10-24 | — | — | CN | disclosed |
| WO-2012120544-A2 | PROCESS FOR N-[2-n-BUTYL-3-[4-[3-(DI-n-BUTYLAMINO) PROPOXY]ENZOYL]BENZOFURAN-5-YL]METHANESULFONAMIDE HYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2012-09-13 | — | — | WO | disclosed |
| CN-102471302-A | Preparation process of dronedarone and its salts | JIANGSU HENGRUI MEDICINE CO | 2012-05-23 | — | — | CN | disclosed |
| WO-2012032545-A1 | PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011099010-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | MAPI PHARMA HOLDINGS (CYPRUS) LIMITED (CY) | 2011-08-18 | — | — | WO | disclosed |
| US-7312345-B2 | Process for the preparation of dronedarone | ISP INVESTMENTS INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20050049302-A1 | Process for the preparation of dronedarone | ISP INVESTMENTS LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040120-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | ISP INVESTMENTS INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130046103-A1 | PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES | CYP2F1, CYP4F3, CYP2D6 | HTR1A 3536/4885DRD2 2714/4885HTR2A 3692/4885 |
| US-20050049302-A1 | Process for the preparation of dronedarone | CACNA1C, CACNA1A, KCNH1 | HTR1A 2491/4885DRD2 500/4885HTR2A 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.